Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990976630> ?p ?o ?g. }
- W2990976630 abstract "Abstract Aim To report the long term results of the CROSS trial with a minimum follow-up of 10 years. Background Neoadjuvant chemoradiotherapy according to the Dutch randomised controlled ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) has become standard of care for patients with cancer of the oesophagus or oesophagogastric junction. Methods Patients with locally advanced resectable squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophagogastric junction were randomised between neoadjuvant chemoradiotherapy (five weekly cycles of intravenous carboplatin [AUC 2 mg/mL per min] and intravenous paclitaxel [50 mg/m² of body-surface area]) with concurrent 41.4 Gy radiotherapy given in 23 fractions of 1.8 Gy, 5 days per week) plus surgery versus surgery alone. Primary endpoint was overall survival, defined from date of randomisation to date of all-cause death or to last day of follow-up. Analysis was by intention-to-treat. Results Between March 2004 and 2008, eight centres enrolled 368 patients. Some 178 were analysed in the chemoradiotherapy plus surgery group and 188 in the surgery alone group. After a median follow-up for surviving patients of 146.6 months (IQR 133.5-156.6), median overall survival was 49.0 months (95%CI 34.7-76.6) in the neoadjuvant chemoradiotherapy plus surgery group compared to 25.1 months (95%CI 19.1-39.4) in the surgery alone group, which was significantly different (HR 0.71 [95%CI 0.55-0.90]; log-rank p=0·005). Ten-year overall survival was 38% (95%CI 31%-45%) in the neoadjuvant chemoradiotherapy followed by surgery group compared to 26% (95%CI 20%-33%) in the surgery alone group (HR 0.69 [95%CI 0.54-0.89]). For patients with squamous cell carcinoma ten-year overall survival was 46% (95%CI 33%-64%) in the neoadjuvant chemoradiotherapy plus surgery group compared to 23% (95%CI 13%-40%) in the surgery alone group. For patients with adenocarcinoma ten-year overall survival was 36% (95%CI 29%-45%) in the neoadjuvant chemoradiotherapy plus surgery group compared to 26% (95%CI 20%-35%) in the surgery alone group. Conclusion Survival benefit of patients with locally advanced resectable squamous cell carcinoma or adenocarcinoma of the oesophagus or oesophagogastric junction receiving neoadjuvant chemoradiotherapy persists for at least 10 years compared to patients undergoing surgery alone." @default.
- W2990976630 created "2019-12-05" @default.
- W2990976630 creator A5006983831 @default.
- W2990976630 creator A5007522548 @default.
- W2990976630 creator A5010394771 @default.
- W2990976630 creator A5010810138 @default.
- W2990976630 creator A5011613312 @default.
- W2990976630 creator A5012050627 @default.
- W2990976630 creator A5013384569 @default.
- W2990976630 creator A5016712877 @default.
- W2990976630 creator A5017475503 @default.
- W2990976630 creator A5018004001 @default.
- W2990976630 creator A5019027181 @default.
- W2990976630 creator A5019150519 @default.
- W2990976630 creator A5024927727 @default.
- W2990976630 creator A5028931587 @default.
- W2990976630 creator A5030943165 @default.
- W2990976630 creator A5039275887 @default.
- W2990976630 creator A5043942519 @default.
- W2990976630 creator A5043992572 @default.
- W2990976630 creator A5044945588 @default.
- W2990976630 creator A5046938432 @default.
- W2990976630 creator A5049787068 @default.
- W2990976630 creator A5051471434 @default.
- W2990976630 creator A5057145168 @default.
- W2990976630 creator A5057147534 @default.
- W2990976630 creator A5064924069 @default.
- W2990976630 creator A5070804045 @default.
- W2990976630 creator A5072902637 @default.
- W2990976630 creator A5073092915 @default.
- W2990976630 creator A5076397116 @default.
- W2990976630 creator A5078429982 @default.
- W2990976630 creator A5082821365 @default.
- W2990976630 creator A5088673015 @default.
- W2990976630 date "2019-11-01" @default.
- W2990976630 modified "2023-09-26" @default.
- W2990976630 title "O200 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL OR JUNCTIONAL CANCER (CROSS)" @default.
- W2990976630 doi "https://doi.org/10.1093/dote/doz092.200" @default.
- W2990976630 hasPublicationYear "2019" @default.
- W2990976630 type Work @default.
- W2990976630 sameAs 2990976630 @default.
- W2990976630 citedByCount "0" @default.
- W2990976630 crossrefType "journal-article" @default.
- W2990976630 hasAuthorship W2990976630A5006983831 @default.
- W2990976630 hasAuthorship W2990976630A5007522548 @default.
- W2990976630 hasAuthorship W2990976630A5010394771 @default.
- W2990976630 hasAuthorship W2990976630A5010810138 @default.
- W2990976630 hasAuthorship W2990976630A5011613312 @default.
- W2990976630 hasAuthorship W2990976630A5012050627 @default.
- W2990976630 hasAuthorship W2990976630A5013384569 @default.
- W2990976630 hasAuthorship W2990976630A5016712877 @default.
- W2990976630 hasAuthorship W2990976630A5017475503 @default.
- W2990976630 hasAuthorship W2990976630A5018004001 @default.
- W2990976630 hasAuthorship W2990976630A5019027181 @default.
- W2990976630 hasAuthorship W2990976630A5019150519 @default.
- W2990976630 hasAuthorship W2990976630A5024927727 @default.
- W2990976630 hasAuthorship W2990976630A5028931587 @default.
- W2990976630 hasAuthorship W2990976630A5030943165 @default.
- W2990976630 hasAuthorship W2990976630A5039275887 @default.
- W2990976630 hasAuthorship W2990976630A5043942519 @default.
- W2990976630 hasAuthorship W2990976630A5043992572 @default.
- W2990976630 hasAuthorship W2990976630A5044945588 @default.
- W2990976630 hasAuthorship W2990976630A5046938432 @default.
- W2990976630 hasAuthorship W2990976630A5049787068 @default.
- W2990976630 hasAuthorship W2990976630A5051471434 @default.
- W2990976630 hasAuthorship W2990976630A5057145168 @default.
- W2990976630 hasAuthorship W2990976630A5057147534 @default.
- W2990976630 hasAuthorship W2990976630A5064924069 @default.
- W2990976630 hasAuthorship W2990976630A5070804045 @default.
- W2990976630 hasAuthorship W2990976630A5072902637 @default.
- W2990976630 hasAuthorship W2990976630A5073092915 @default.
- W2990976630 hasAuthorship W2990976630A5076397116 @default.
- W2990976630 hasAuthorship W2990976630A5078429982 @default.
- W2990976630 hasAuthorship W2990976630A5082821365 @default.
- W2990976630 hasAuthorship W2990976630A5088673015 @default.
- W2990976630 hasConcept C121608353 @default.
- W2990976630 hasConcept C126322002 @default.
- W2990976630 hasConcept C141071460 @default.
- W2990976630 hasConcept C168563851 @default.
- W2990976630 hasConcept C203092338 @default.
- W2990976630 hasConcept C2776694085 @default.
- W2990976630 hasConcept C2778239845 @default.
- W2990976630 hasConcept C2778292576 @default.
- W2990976630 hasConcept C2778424827 @default.
- W2990976630 hasConcept C2779742542 @default.
- W2990976630 hasConcept C2781182431 @default.
- W2990976630 hasConcept C2781451048 @default.
- W2990976630 hasConcept C509974204 @default.
- W2990976630 hasConcept C530470458 @default.
- W2990976630 hasConcept C71924100 @default.
- W2990976630 hasConceptScore W2990976630C121608353 @default.
- W2990976630 hasConceptScore W2990976630C126322002 @default.
- W2990976630 hasConceptScore W2990976630C141071460 @default.
- W2990976630 hasConceptScore W2990976630C168563851 @default.
- W2990976630 hasConceptScore W2990976630C203092338 @default.
- W2990976630 hasConceptScore W2990976630C2776694085 @default.
- W2990976630 hasConceptScore W2990976630C2778239845 @default.
- W2990976630 hasConceptScore W2990976630C2778292576 @default.
- W2990976630 hasConceptScore W2990976630C2778424827 @default.
- W2990976630 hasConceptScore W2990976630C2779742542 @default.